While it is known that the composition of adipose tissue reflects dietary fatty acid intake, the relationship between diet and the plasma phospholipid composition may be relatively weak (Horrobin et al., 1989; van Houwelingen et al., 1989) . These is remarkably little variation in plasma phospholipid fatty acid composition among normal populations living in widely different geographical locations. It has been suggested that this relative constancy may make their measurement useful in disease states (Horrobin et al., 1989) .
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Bladder cancer is a common neoplasm which affects three times as n;any men as women and is a disease of middle-aged and elderly patients. The majority of these tumours are papillary in type and can be managed using transurethral surgical techniques. Many of these patients, however, will develop recurrences of their neoplasms and hence require cystoscopic follow-up examinations. We have measured the levels of the essential fatty acids in the plasma phospholipids of patients with bladder cancer to establish the possible role of these measurements in clinical practice. Essentialfatty acid nomenclature There are two families of essential fatty acids derived from linoleic (18:2n6) and alpha-linolenic (18:3n3) acids. These parent compounds undergo a process of elongation and desaturation as outlined in Figure 1 . Some of the subsequent compounds are substrates for the eicosanoids -prostaglandins, prostacyclin, thomboxanes and leukotrienes.
Materials and methods

Patients
Ninety-eight patients with a proven histological diagnosis of bladder cancer, who were attending for regular check cystoscopy, had fasting blood samples taken before induction of anaesthesia for cystoscopy. The fasting blood samples were taken into EDTA-treated tubes, centrifuged at 800 g for 5 Plasma samples (1 ml) were extracted with chloroform:methanol (2:1). The extract was filtered through sodium sulphate, evaporated to dryness, and taken up in 0.5 ml chloroform: methanol. The lipid fractions were separated by thin-layer chromatography on silica gel plates. The phospholipid fraction, which seems to reflect essential fatty acid changes most sensitively, was methylated using boron trifulouride-methanol. The resulting methyl esters of the fatty acids were separated and measured using a Hewlett-Packard 5880 gas chromatograph with a 6 foot column packed with 10% silar on chromasorb WAW 106/230. The carrier gas was helium (30 ml min '). Oven temperature was programmed to rise from 165°C to 190°C at 2°C min-'. Detector For the two groups of patients with bladder cancer, the means and standard deviations for each fatty acid were calculated. The two groups were then compared using the Mann-Whitney U-Test. The fatty acids levels in the two groups, both separately and in combination, were then compared with the normal controls using the unpaired t-test.
Results
Of the 98 patients entered in the study, 55 had active disease (i.e. recurrence tumour at cystoscopy) and 43 had inactive disease. The age and sex distribution of the two groups is outlined in Table I , and shows that the two groups are comparable by age and sex. The results of the fatty acid analysis of the plasma phospholipids of the two groups and a control population is shown in Table II . Comparison of all the cancer patients with the control population showed significantly lower plasma levels of the major dietary n-6 EFA, linoleic acid (P<0.001, t-test), and of all its metabolites except 20:3n6 (dihomogammalinolenic acid) and 22:5n6. The level of the major dietary n-3 EFA, alpha-linolenic acid, was not significantly lower than the control level, but the levels of its metabolites were significantly lower (P<0.001, t-test).
No significant differences were found, using the MannWhitney U-Test, between the active and inactive disease groups.
Discussion
We have demonstrated significant differences in the plasma phospholipid profiles of patients with histologically proven bladder cancer, when compared to a control population. There were, however, no significant differences between those patients with active bladder disease and those with inactive disease. Measurement of the essential fatty acids in the plasma phospholipids of patients with bladder cancer is not, therefore, a useful marker of disease activity.
Changes in the plasma levels of the essential fatty acids in patients with cancer may be related to a pathological metabolism and incorporation into phospholipids of the various fatty acids. Similar variations have been demonstrated in patients with atopic eczema , premenstrual syndrome (Brush et al., 1984) and those at risk of developing coronary heart disease (Miettinen et al., 1982) .
It is possible that in patients with cancer, the cancer itself may be responsible for changes in essential fatty acid metabolism. Tumour cells tend to have a decreased activity of the desaturase enzymes, particularly the delta-6-desaturase (Reitz et al., 1977; Bailey, 1977; Horrobin, 1980) . This is in keeping with the known enzymatic differences between cancer cells and normal control cells, such as changes in enzymatic activity, concentration and composition (Weber, 1977; Pretlow et al., 1985) . This difference in activity of the tumour cell delta-6-desaturase leads to lower levels of the fatty acid derivatives in tumour cells. This seems to be mirrored in the plasma levels of the fatty acids, perhaps reflecting the diverse metabolic effects caused by the presence of a tumour. On the other hand, the lack of any difference between the active and inactive patients in our study may indicate that the presence of active tumour has no effect on systemic essential fatty acid metabolism.
An alternative equally interesting possibility is that the fatty acid abnormalities may in some way be involved in the pathogenesis of the tumour. A dietary deficiency of essential fatty acids does not reliably produce tumours except in the urinary tract. Rats deprived of dietary essential fatty acids consistently show pre-malignant and malignant change in the transitional epithelium of the urinary tract (Monis et al., 1982) . There is thus the possibility that a deficit in essential fatty acids, as we have shown in our patients, may predispose to the development of bladder cancer. It is even conceivable that essential fatty acid supplementation may be of value in preventing or treating bladder cancer.
